TearLab Announces Corporate Name Change to Trukera Medical; Targets Corneal Health
TearLab announced that it will be expanding its position in corneal health under the new name Trukera Medical. The rebranding reflects the company’s vision and future growth strategy targeting a broader set of unmet needs across corneal health.
“We continue to remain dedicated to the advancement of corneal health. Our decision to rebrand as Trukera Medical represents our history as pioneers of point-of-care testing for corneal disease, while also more clearly reflecting where we’re going next,” Trukera Medical CEO Adam Szaronos said in a company news release. “We expect to see strong continued growth ahead with point-of-care diagnostics, driven primarily by practices specializing in cornea and premium cataract/refractive surgery. This is where the physician and patient need is greatest for advanced corneal health, and it’s where we find additional unmet needs that we are positioned to address for our customers. Our vision is to be the world’s leading and most trusted corneal health company for providers and patients, and the leadership team and I are excited to introduce a name that represents this expanded vision.”
TearLab introduced osmolarity testing as an objective diagnostic tool in the eye care market with the TearLab Osmolarity System in 2010. Since then, over 24 million tests with the device have been completed worldwide. The ASCRS OSD Algorithm deemed osmolarity an “essential” preoperative diagnostic test for cataract and refractive surgeries.[1] It will remain a flagship device in the Trukera Medical portfolio.
“Corneal health is an exciting focus for us because precise, predictive and practical corneal evaluation can inform treatment in all aspects of ocular health,” said James V. Mazzo, Executive Chairman of the Board at Trukera Medical. “Customers have expanded the use of osmolarity testing from aiding in the diagnosis and management of corneal disease to ensuring risk factors are identified for minimizing refractive surprises after surgery. As Trukera, we’re looking forward to helping improve patients’ lives even further by advancing doctors’ capabilities around corneal health.”
The first new product under the Trukera Medical brand will be announced later this month and launched at the upcoming World Cornea Congress and American Academy of Ophthalmology. To learn more and get the latest news, visit www.TearLab.com.
References
1. Starr CE, Gupta PK, Farid M, et al. An algorithm for the preoperative diagnosis and treatment of ocular surface disorders. J Cataract Refract Surg. 2019 May;45(5):669-684. doi: 10.1016/j.jcrs.2019.03.023.